ALHI Announces Appointment of Lusia Guthrie as Chair

ALHI Announces Appointment of Lusia Guthrie as Chair



The Australian Lung Health Initiative (ALHI) is pleased to announce today the appointment of Lusia Guthrie as Chair.

Guthrie brings to ALHI over 35 years of experience in the pharmaceutical and bioscience industries as an experienced CEO, technology developer and medtech entrepreneur.   She is a member of the Australian Institute of Company Directors and currently serves as Chair for the BioMelbourne Network, along with the Steering Committee of the Medical Device Partnering Program in Victoria.

“I’m very honoured to have been elected as Chair for ALHI,” said Guthrie.  “With 4Dx bringing their technology to world markets, they’re truly on the brink of making medical history.  Now seeing them lead the charge to further develop that innovation into another world-first is very exciting.  I feel very privileged to be a part of it.”

4Dx CEO and ALHI Chief Investigator, Andreas Fouras, said he was delighted to have Guthrie on board.  “We’re very fortunate to have someone of Lusia Guthrie’s caliber and experience to help us lead ALHI.  The birth of ALHI is an opportunity to make such a strong, positive and meaningful impact on children’s lung health across the globe, and Lusia’s passion and proven track record in bringing innovative products to global markets is invaluable. We’re very excited to have her on the ALHI team.”

Visit Lusia Guthrie’s LinkedIn page here.
Visit the 4Dx website here.

Posted:  20 June 2019